VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
PRQRProQR Therapeutics N.V.$1.44$152M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPRQREarnings History

PRQR logoProQR Therapeutics N.V. (PRQR) Earnings History

Net Loss

13 years of earnings data (2013–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$46M
● Net Loss
TTM EPS (Diluted)
$-0.43
Per share, diluted
YoY EPS Growth
-11.8%
Declining
Net Margin
-265.2%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-275.9%
Gross Margin83.0%
Return on Equity-58.8%
Return on Assets-28.9%
Record Annual Net Income-$3MFY2013
Record Quarterly EPS$0.01Q1 2015
Consecutive Profitable Years0years
Q1 2026
Net Income-$14M
EPS (Diluted)$-0.13
YoY Growth-11.8%Declining
QoQ Growth-53.9%Declining

Loading earnings history...

ProQR Therapeutics N.V. (PRQR) Earnings Overview

As of June 12, 2026, ProQR Therapeutics N.V. (PRQR) reported trailing twelve-month net income of -$46M, reflecting -11.8% year-over-year growth. The company earned $-0.43 per diluted share over the past four quarters, with a net profit margin of -265.2%.

Looking at the long-term picture, PRQR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2013.

ProQR Therapeutics N.V. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including EDIT (-$109M net income, -395.0% margin), NTLA (-$395M net income, -609.9% margin), CRSP (-$569M net income, -16569.8% margin), PRQR has outperformed on profitability metrics. Compare PRQR vs EDIT →

PRQR Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
PRQR logoPRQRCurrent
-$46M$-0.43-265.2%-58.8%-11.8%—
EDIT logoEDIT
-$109M$-1.11-395.0%-198.1%+37.5%
NTLA logoNTLA
-$395M$-3.33-609.9%-53.5%+27.4%
CRSP logoCRSP
-$569M$-5.92-16569.8%-30.2%-49.1%
BEAM logoBEAM
-$65M$-0.63-57.2%-8.1%+82.3%
ARWR logoARWR
-$301M$-2.11-0.2%-0.5%+99.8%
Best in group
Lowest in group

PRQR Historical Earnings Data (2013–2025)

13 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$41M-45.9%-$42M$-0.38-265.2%-275.9%
2024-$28M+1.3%-$30M$-0.34-146.9%-161.2%
2023-$28M+56.4%-$32M$-0.35-431.7%-489.1%
2022-$64M-6.1%-$65M$-0.91-1792.5%-1813.0%
2021-$61M-30.4%-$57M$-0.96-4549.8%-4285.4%
2020-$47M+17.9%-$42M$-0.93-4525.3%-4117.4%
2019-$57M-53.8%-$57M$-1.38-2935.6%-2971.8%
2018-$37M+15.5%-$36M$-1.08-746.7%-734.5%
2017-$44M-11.6%-$40M$-1.72--
2016-$39M-87.7%-$40M$-1.67-1713.5%-1734.1%
2015-$21M-71.8%-$27M$-0.89-221.5%-287.1%
2014-$12M-272.8%-$16M$-0.55-3874.4%-5259.1%
2013-$3M--$3M$-0.15--

Download Data

Export PRQR earnings history in CSV or JSON format

Free sign-in required to download data

What if you invested $1,000 in PRQR back in 2013?

Total return with dividends reinvested · 13+ years of data

Calculate Returns

How much would $100/month in PRQR be worth today?

Dollar cost averaging vs lump sum · see how regular investing compounds over time

Run the Numbers

Is PRQR Undervalued Right Now?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

PRQR vs LLY — which is the better buy?

Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.

Compare Now

PRQR — Frequently Asked Questions

Quick answers to the most common questions about buying PRQR stock.

What is PRQR earnings per share (EPS)?

PRQR trailing twelve-month (TTM) diluted EPS is $-0.43, reflecting -11.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2013 to 2025 is available in the table on this page.

What is ProQR Therapeutics N.V.'s net income?

ProQR Therapeutics N.V. (PRQR) trailing twelve-month net income is $-46M as of 2025. Earnings declined -11.8% year-over-year.

Is PRQR profitable?

PRQR is not currently profitable on a TTM basis, reporting a net loss of $-46M. Net margin is -265.2%. Investors should monitor for a return to profitability.

What is PRQR's earnings growth rate?

PRQR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2013 to 2025.

What are PRQR's profit margins?

ProQR Therapeutics N.V. net profit margin is -265.2%, operating margin is -275.9%, and gross margin is +83.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -58.8%.

Is PRQR growing earnings?

PRQR earnings are declining — EPS fell -11.8% year-over-year. TTM net income dropped to $-46M. This contrasts with the 5-year CAGR of N/A.

What was PRQR's best earnings year?

ProQR Therapeutics N.V.'s highest annual net income on record is $-3M, achieved in fiscal year 2013. Earnings history on this page spans 2013 to 2025 and includes all annual and quarterly figures.

What were PRQR's earnings last quarter?

PRQR's most recent reported quarter was Q1 2026. Net income was $-14M with diluted EPS of $-0.13. For a full breakdown of all quarters, see the quarterly earnings table on this page.

PRQR Earnings Over Time (2013–2025)

Net income & EPS — annual and quarterly view